Kit for Treatment of Cancer
AssigneeRedoxia Israel Ltd.
InventorsArnold Hoffman, Lee M. Spetner, Michael Burke
Life of this patent
Estimating the term…
Loading patent…
AssigneeRedoxia Israel Ltd.
InventorsArnold Hoffman, Lee M. Spetner, Michael Burke
Estimating the term…
The present invention relates to a kit for the treatment of cancer comprising (a) a container for containing a first compound (i) or a precursor thereof, said first compound or precursor being a compound that oxidizes glutathione (GSH); (b) a container for containing a second compound (ii) or a precursor thereof, said second compound or precursor being a compound that forms an adduct or conjugate with GSH; (c) a container for containing a third compound (iii) or a precursor thereof, said third compound or precursor being a compound that inhibits the rate-limiting enzyme of GSH biosynthesis, gamma-glutamylcysteine synthetase (GCS); and (d) a container for containing a fourth compound (iv) or a precursor thereof, said fourth compound or precursor being a compound that inhibits the enzyme responsible for the conversion of GSSG to GSH, glutathione reductase (GR).
A kit comprising:
(canceled)
A kit according to claim 8, wherein said cancer is leukemia or lymphoma.
A kit according to claim 8, wherein said cancer is bladder, bone, brain, breast, cervical, colon, esophageal, kidney, laryngeal, liver, lung, melanoma, ovary, pancreas, prostate, rectal, skin, testicular, or uterine cancer.
A method of selectively inducing apoptosis in cancerous cells of a cancer patient, said method comprising administering to said cancer patient a pharmaceutically effective amount of a combination of 4 compounds effective to increase the redox potential of the cancerous cells to a threshold potential that induces apoptosis, while the increase in redox potential in non-cancerous cells does not induce apoptosis, wherein in said combination of 4 compounds each compound belongs to a different category selected from the group consisting of categories (i) to (iv):
A method of selectively inducing apoptosis in cancerous cells of a cancer patient, said method comprising administering to said cancer patient pharmaceutically effective amount of a combination of 4 compounds effective to prevent phosphorylation of the retinoblastoma protein (pRB) in said cancerous cells, wherein in said combination of 4 compounds each compound belongs to a different category selected from the group consisting of categories (i) to (iv):
16-19. (canceled)
A method of selectively inducing apoptosis in cancerous cells of a cancer patient, said method comprising administering to said cancer patient pharmaceutically effective amount of a combination of 4 compounds effective to prevents release of transcriptional factors from the retinoblastoma protein (pRB) in said cancerous cells, wherein in said combination of 4 compounds each compound belongs to a different category selected from the group consisting of categories (i) to (iv):
21-24. (canceled)
A method of selectively inducing apoptosis in cancerous cells of a cancer patient, said method comprising administering to said cancer patient a pharmaceutically effective amount of a combination of 4 compounds such that the effect of the four compounds on the cancer cells continuously remain for the duration of time required to arrest the cancer cells in G1pm until apoptosis is induced whereas the normal cells in G1pm can enter G0 and remain unharmed, wherein each compound of the combination of 4 compounds belongs to a different category selected from the group consisting of categories (i) to (iv):
A method of selectively inducing apoptosis in cancerous cells of a cancer patient by decreasing the [GSH]2/[GSSG] ratio such that the redox potential E in said cancerous cells is increased to or above the threshold potential, while the increase in redox potential in non-cancerous cells is such that it remains below the threshold potential, said method comprising administering to said cancer patient a pharmaceutically effective amount of a combination of 4 compounds effective for decreasing the [GSH]2/[GSSG] ratio such that the redox potential E in said cancerous cells is increased to or above the threshold potential, wherein each compound belongs to a different category selected from the group consisting of categories (i) to (iv):
29-39. (canceled)
Dependencies are inferred from the claim text.